Taniguchi Natsuki, Satou Akira, Ito Takanori, Nakaguro Masato, Tsuzuki Toyonori
Department of Surgical Pathology, Aichi Medical University Hospital, Nagakute, Japan.
Department of Pathology and Laboratory Medicine, Nagoya University Hospital, Nagoya, Japan.
Pathol Int. 2023 Jul;73(7):317-322. doi: 10.1111/pin.13346. Epub 2023 Jun 14.
Branchioma is a rare benign neoplasm occurring in the lower neck. Occurrence of malignant neoplasms arising in branchioma is extremely rare. Here, we report a case of adenocarcinoma arising in branchioma. A 62-year-old man had a right supraclavicular mass measuring 7.5 cm in diameter. The tumor contained an adenocarcinoma component encapsulated in a benign branchioma component. The adenocarcinoma component consisted of high- and low-grade components, with the former accounting for 80% of the adenocarcinoma. The high-grade component was immunohistochemically characterized by diffuse strong p53 expression, while the low-grade component and branchioma component were negative for p53. Targeted sequencing analysis for the branchioma and adenocarcinoma components revealed that the adenocarcinoma component harbored pathogenic mutations in KRAS and TP53. No definitive oncogenic drivers were detected in the branchioma component. Based on these immunohistochemical and molecular findings, we suggest that the KRAS mutation contributed to the pathogenesis of the adenocarcinoma, and the TP53 mutation played a key role in the transition from low-grade to high-grade adenocarcinoma.
鳃裂瘤是一种发生于下颈部的罕见良性肿瘤。起源于鳃裂瘤的恶性肿瘤极为罕见。在此,我们报告一例起源于鳃裂瘤的腺癌病例。一名62岁男性有一个直径7.5厘米的右锁骨上肿块。肿瘤包含一个被良性鳃裂瘤成分包裹的腺癌成分。腺癌成分由高级别和低级别成分组成,前者占腺癌的80%。高级别成分免疫组化特征为p53弥漫性强表达,而低级别成分和鳃裂瘤成分p53为阴性。对鳃裂瘤和腺癌成分进行的靶向测序分析显示,腺癌成分存在KRAS和TP53的致病突变。在鳃裂瘤成分中未检测到明确的致癌驱动因素。基于这些免疫组化和分子学发现,我们认为KRAS突变促成了腺癌的发病机制,而TP53突变在低级别腺癌向高级别腺癌的转变中起关键作用。